Venus showcased its proprietary platform technology “Stealth Targeted Nanoparticles (STN)” at World AMR Congress-2018.
Healthcare-Associated Infections (HAIs) represent a huge burden of AMR in the developed world. Unfortunately, most drugs available to treat serious infections caused by gram-negative bacteria can only be administered intravenously as one or more of the active compounds have poor oral bioavailability. To overcome this hurdle, a new technology — Stealth Targeted Nanoparticles (STN) — is being developed to enable drugs such as Ceftazidime, Meropenem and BL-BLI combinations, etc. with poor bioavailability to be delivered orally.
